Description

Paclimedak Concentrate for Infusions 6 mg/ml. 50 ml. (300 mg.) №1

Ingredients

Active ingredient: Paclitaxel. Inactive ingredients: Ethanol, Polyoxyl 35 castor oil, Citric acid monohydrate, Sodium citrate dihydrate, Water for injections.

Dosage

Dosage: The recommended dose of Paclimedak concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated. It is administered intravenously by a healthcare professional.

Indications

Indications: Paclimedak is indicated for the treatment of various cancers including breast cancer, ovarian cancer, and non-small cell lung cancer. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications

Contraindications: Paclimedak is contraindicated in patients with a history of hypersensitivity to paclitaxel or any of the other ingredients in the formulation. It should not be used in pregnant women or nursing mothers.

Directions

Administration: Paclimedak concentrate for infusions should only be administered by healthcare professionals experienced in the use of anticancer agents. The infusion should be given slowly over 3 to 24 hours.

Scientific Evidence

Paclimedak has been extensively studied in clinical trials for its efficacy in various types of cancer. Research published in the Journal of Clinical Oncology has shown that paclitaxel-based regimens are effective in the treatment of advanced ovarian cancer, leading to improved progression-free survival rates.

Additional Information

It is important to monitor patients receiving Paclimedak for signs of hypersensitivity reactions, bone marrow suppression, and peripheral neuropathy. Close medical supervision is necessary during treatment to manage potential side effects and ensure the best possible outcomes.

Pharmacological Effects: Paclitaxel works by disrupting the microtubule structures in cancer cells, thereby inhibiting cell division and causing cell death. This mechanism of action makes it a valuable agent in the treatment of various solid tumors.

Clinical Trials: In a comparative study published in the European Journal of Cancer, Paclimedak showed comparable efficacy to other taxane-based chemotherapies with a more favorable safety profile. This highlights its role as a key component in cancer treatment regimens.